Alkermes PLC Company Profile (NASDAQ:ALKS)

Alkermes PLC trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes PLC (NASDAQ:ALKS) posted its earnings results on Thursday, April, 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.07. The business had revenue of $191.80 million for the quarter, compared to analyst estimates of $195.79 million. Alkermes PLC had a negative return on equity of 9.76% and a negative net margin of 25.61%. The firm's revenue for the quarter was up 22.3% compared to the same quarter last year. During the same period last year, the company posted ($0.16) EPS. View Alkermes PLC's Earnings History.

Alkermes PLC is scheduled to release their next quarterly earnings announcement on Thursday, July, 27th 2017. View Earnings Estimates for Alkermes PLC.

9 analysts have issued 1-year price targets for Alkermes PLC's stock. Their predictions range from $51.00 to $78.00. On average, they expect Alkermes PLC's stock price to reach $64.00 in the next twelve months. View Analyst Ratings for Alkermes PLC.

Here are some recent quotes from research analysts about Alkermes PLC stock:

• 1. Cowen and Company analysts commented, "ALKS reported Q1:17 results which came in below expectations." (4/28/2017)
• 2. Cantor Fitzgerald analysts commented, "We remain cautious on ALKS stock because we believe it reasonable that the company may not be able to file for regulatory approval of ALKS 5461 (for treating major depressive disorder, MDD) with data from only one positive Phase 3 trial from the three studies that comprise the FORWARD clinical program. We also remain unconvinced that the company will successfully transition from a developer of drug formulation technologies (historically applied to partner's assets) to a developer of proprietary products. As noted in a report we recently published on the evolving multiple sclerosis (MS) landscape, we believe new market entrants could challenge existing drug franchises, in particular that of Biogen (BIIB, Neutral, $277). Even if ALKS 8700 does not reduce GI side effects relative to that experienced with Tecfidera, we believe ALKS would likely seek approval anyway given the hegemony BIIB enjoys in the MS fumarate drug market." (3/16/2017)
• 3. According to Zacks Investment Research, "Alkermes boasts a diversified portfolio of products targeting major CNS disorders including schizophrenia, depression, addiction and multiple sclerosis. Revenues are driven not only by the company’s royalty and manufacturing business, but also by a strong performance of Vivitrol and Aristada. Alkermes sees both Vivitrol and Aristada as growth drivers. While Vivitrol should benefit from the newly passed legislation, CARA, securing reimbursement and access for Aristada also bodes well. Meanwhile, Alkermes’ progress with its pipeline has been impressive. Focus should be on the same as the company expects important data readouts over the next several quarters. Given its history of pipeline setbacks, any obstacle in the process of development of these candidates would weigh heavily on the stock. Stiff competition and dependence on partners remains a threat. Shares of the company have underperformed the broader industry year to date." (12/13/2016)
• 4. J P Morgan Chase & Co analysts commented, "Importantly 5461 continued to be well tolerated, in line with prior studies. ALKS plans to meet with the FDA in early 1Q17 to discuss filing, and we continue to think positive FORWARD-5 data makes the totality of the data approvable [...] Further confirmation of an NDA filing based on data in hand, as well as, clarity on the filing timeline will be key in 2017." (10/21/2016)
• 5. Morgan Stanley analysts commented, "We are raising our PT from $18 (11x old F17e of 1.64) to $23 (16x new F17e of $1.42) since downside from US MFA (antibiotic medicated feed additive) pressures appears limited." (9/2/2016)

Some companies that are related to Alkermes PLC include Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), Icon Plc (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Exact Sciences Corporation (EXAS), Galapagos NV (GLPG), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX) and Sage Therapeutics (SAGE).

Alkermes PLC's management team includes the folowing people:

• Richard F. Pops, Chairman, President, and CEO
• James M. (Jim) Frates, SVP, CFO, and Treasurer
• Gordon G. Pugh, SVP, COO, and Chief Risk Officer
• Richard F. Pops, Chairman of the Board, Chief Executive Officer
• Shane M. Cooke, President
• James M. Frates, Chief Financial Officer, Senior Vice President
• Kathryn L. Biberstein, Executive Vice President, Chief Administrative Officer, Chief Compliance Officer, Secretary
• Elliot W. Ehrich M.D., Executive Vice President - Research and Development and Chief Medical Officer
• Craig Hopkinson, Senior Vice President - Clinical Development and Medical Affairs, Chief Medical Officer
• Michael J. Landine, Senior Vice President - Corporate Development

Alkermes PLC's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Meditor Group Ltd (0.67%), GW&K Investment Management LLC (0.20%), Fisher Asset Management LLC (0.07%), Roanoke Asset Management Corp NY (0.05%), APG Asset Management N.V. (0.04%) and Nisa Investment Advisors LLC (0.03%). Company insiders that own Alkermes PLC stock include David Joseph Gaffin, David W Anstice, Elliot Ehrich, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Institutional Ownership Trends for Alkermes PLC.

Alkermes PLC's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Roanoke Asset Management Corp NY, Eqis Capital Management Inc., Independent Portfolio Consultants Inc., Bank of Montreal Can and Fisher Asset Management LLC. Company insiders that have sold Alkermes PLC stock in the last year include David Joseph Gaffin, Elliot Ehrich, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Insider Buying and Selling for Alkermes PLC.

Alkermes PLC's stock was bought by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Mn Services Vermogensbeheer B.V., Insight Capital Research & Management Inc., US Bancorp DE, Daiwa SB Investments Ltd., Creative Planning, Aperio Group LLC and Capstone Asset Management Co.. View Insider Buying and Selling for Alkermes PLC.

Shares of Alkermes PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Alkermes PLC stock can currently be purchased for approximately $57.73.